Table 1.
Patients’ Characteristics at Baseline
| Characteristics | MBC, n=177, n (%) |
|---|---|
| Age, years | |
| Median (range) | 53 (29–74) |
| Menopausal status | |
| Postmenopausal | 105 (59.3) |
| Premenopausal | 72 (40.7) |
| De novo | 68 (38.4) |
| Disease‐free interval, months | |
| < 24 | 49 (27.7) |
| ≥ 24 | 60 (33.9) |
| Subgroups | |
| HR+/HER2- | 87 (58.2) |
| HER2+ | 30 (16.9) |
| Triple-negative | 60 (33.9) |
| Number of metastatic sites | |
| 1 | 51 (28.9) |
| 2 | 62 (35.0) |
| ≥ 3 | 64 (36.1) |
| Metastatic sites | |
| Liver | 33 (18.6) |
| Lung | 67 (37.9) |
| Bone | 94 (53.1) |
| Visceral disease | 96 (54.2) |
| First-line treatment | |
| Endocrine therapy | 44 (24.9) |
| Anti-HER2 therapy | 29 (16.4) |
| Chemotherapy | 104 (58.7) |
Abbreviations: HR+, hormone receptor positive; HER2-, human epidermal growth factor receptor 2 negative.